Q&A with Peter Soelkner, managing director of Vetter Pharma International - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Peter Soelkner, managing director of Vetter Pharma International

Pharmaceutical Technology
Volume 33, Issue 8, pp. 60



PharmTech:
How do you stay abreast of new developments in the industry?

Soelkner:
To understand the newest challenges and developments in the pharmaceutical industry, it is critical that we walk in our clients' shoes. We must recognize their needs and understand what ultimate success means for them.

Working with 18 to 20 of the top pharmaceutical companies in the world gives us a bird's eye view of industry challenges. We can use this opportunity to identify and respond to industry changes as they happen and work to stay a step ahead.

By working directly with our clients to draft blueprints for individual projects, we are able not only to share information about industry events, but to create product life-cycle management tools to address industry developments. By providing advanced customer service and understanding our clients' needs, we are able to obtain critical information that allows us to respond to the ever-changing pharmaceutical landscape.

PharmTech:
Do you see a new industry trend emerging?

Soelkner:
One of the emerging trends in the industry, especially among the larger companies, is the investment in proactive early product life-cycle management strategies throughout a product's entire life. Rather than try to maintain their drugs on the market, many companies have relied on their ability to keep the pipeline filled with new products. But with the number of new drugs declining, development costs rising, and the patents on some of the biggest drugs on the market set to expire in the next few years, companies are looking at life-cycle management approaches to maximize the profitability throughout a product's lifespan. Getting a drug on the market is no longer enough. Keeping it there and managing its success is just as crucial.

Developing new markets and new applications for existing products, completing product reformulation, and extending the product life cycle are necessities in the marketplace. Product life-cycle management is playing an important role much earlier in the development process than before. Companies prepared with a vigorous product life-cycle management concept and schedule will be better positioned to succeed in this difficult economic environment.

Peter Soelkner will be giving the opening address at Vetter’s 2nd Drug Management Leadership Conference to be held on September 23 and 24 in Lindau on Lake Constance, Germany.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here